Hence, we have produced two novelseries of drug-like compounds that can selectively and potently inhibitthe activity of 17β-HSD10, both in vitro and in vivo, placing them as real potential leads in the treatmentof either Alzheimer’s disease and/or specific cancers. This evidence concerns the gene HSD17B10 and early-onset autosomal dominant Alzheimer disease.